Angiogenic factors as promising therapeutic targets in sepsis: where are we now?
Angiogenic factors as promising therapeutic targets in sepsis: where are we now?
复制标题
DOI:
10.1097/ccm.0000000000000666
复制
发表时间:
2015
影响因子:
8.8
通讯作者:
Ru-yuan Zhang;Lei Li;Hong-ping Qu;Yaoqing Tang
中科院分区:
文献类型:
--
作者:
Ru-yuan Zhang;Lei Li;Hong-ping Qu;Yaoqing Tang
Critical Care Medicine www.ccmjournal.org e31 initial analysis of 1,404 subjects (left column) (4), the adjusted probability of 1-year mortality by BMI category in all patients with two presepsis weight recordings (middle column), and adjusted mortality of patients by BMI category at 0% change in weight between the two preceding surveys (right column). Our results are consistent with our initial analysis and not statistically distinguishable from the original report. Reduced mortality with greater BMI categories persists in patients with stable weight trajectories (right column), as well as in patients with declining and rising weight trajectories, respectively (data not shown). Overall, we conclude that the association of BMI with improved mortality after severe sepsis persists after considering weight trajectory. We do note, of course, that in this smaller population, the differences between BMI categories are no longer statistically significant. This is a result of lack of precision in the estimates resulting from the smaller sample size not from any change in the best-estimated difference in effects between the groups in this smaller population. Even within this nationally representative, decade-long longitudinal survey, the study population is too small to define the impact of weight trajectory on mortality after severe sepsis to rule in or rule out clinically meaningful effect sizes precisely. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. Supported, in part, by grants T32 HL007749 from the National Institutes of Health (Dr. Prescott) Dr. Prescott and her institution received grant support from a NIH T32 training grant and Dr. Iwashyna received support for article research from the NIH and disclosed government work. His institution received grant support (IIR 11–109) from the NIH/Department of Veterans Affairs HSR&D (Dr. Iwashyna does a lot of work in sepsis research).